External broker reports(aggregated public sources), Nirmal Bang

Nirmal Bang

External broker reports(aggregated public sources)

A Relationship Beyond Broking

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

Thematic (Sector/Industry)

<ul><li>4QFY22 is expected to be a flattish quarter for most Pharma companies in our coverage universe.</li><li>We expect a few companies to benefit from the US market, including Sun Pharma, Natco Pharma, Biocon and Cipla.</li><li>Sun Pharma is expected to gain on Winlevi ramp-up and growth in key products, including Cequa and Ilumya Revlimid launch in March 2022 will see some favourable impact in 4QFY22.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

4QFY22 is expected to be a flattish quarter for most Pharma companies in our coverage universe.We expect a few companies to benefit from the US market, including Sun Pharma, Natco Pharma, Biocon and Cipla.Sun Pharma is expected to gain on Winlevi ramp-up and growth in key products, including Cequa and Ilumya Revlimid launch in March 2022 will see some favourable impact in 4QFY22.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaceutical Sector: Sequentially Flattish Quarter Expected

Indian Accounting Research Analyst, Trudence Capital Advisors

Nitin Mangal

Indian Accounting Research Analyst

Trudence Capital Advisors

Trudence Capital Advisors Private Limited is a SEBI-registered Research Analyst, holding SEBI registration number INH000015747. Our firm is dedicated to providing independent and unbiased research on Indian mid to large-cap companies. Trudence Capital is known for its counter-consensus views, with a focus on forensic research and on-ground primary investigations. Our research approach is thorough, involving detailed analysis of accounting practices and governance, alongside extensive channel checks.

Independent & Unbiased Research

Forensic Accounting

Dishman Carbogen Amcis / Forensic Accounting

<a href="https://www.smartkarma.com/entities/dishman-pharmaceuticals-ch" target="_blank" data-smartkarma-citation="entities:9105:1" rel="noopener"></a><a href="https://www.smartkarma.com/entities/dishman-carbogen-amcis-ltd" target="_blank" data-smartkarma-citation="entities:33022:1" rel="noopener">Dishman Carbogen Amcis (DCAL IN)</a> has major focus on contract research and manufacturing services and manufacture of Vitamins and disinfectants.
The company after being merged with Carbogen Amcis AG struggled to report healthy return ratios which indicates poor capital allocation policy. Also, few transactions indicates possible governance lapses in the company.

Dishman Carbogen Amcis (DCAL IN) has major focus on contract research and manufacturing services and manufacture of Vitamins and disinfectants.
The company after being merged with Carbogen Amcis AG struggled to report healthy return ratios which indicates poor capital allocation policy. Also, few transactions indicates possible governance lapses in the company.

Forensic Analysis: Dishman Carbogen Amcis Ltd.

India

Dishman Carbogen Amcis Limited manufactures and distributes specialty pharmaceutical products. The Company develops vitamins, chemicals, phosphonium, disinfectants, and parental drugs. Dishman Carbogen Amcis serves cusotmers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dishman Carbogen Amcis (DCAL IN)

Pharmaceutical Sector: Sequentially Flattish Quarter Expected

4QFY22 is expected to be a flattish quarter for most Pharma companies in our coverage universe. We expect a few companies to benefit from the US...

Nirmal Bang

Forensic Analysis: Dishman Carbogen Amcis Ltd.

Few transactions indicates possible lapses in the governance practices of the company. The acquisition of Dishman Biotech Limited raises more...

Nitin Mangal

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)